Contineum Therapeutics
Pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications.
60 employees · est. 2017 · San Diego, United States
Novoron Bioscience
Pioneering lipoprotein-receptor drug development to repair damage and degeneration to the brain, spinal cord and beyond.
17 employees · est. 2014 · San Diego, United States
Novoron Bioscience is the older company (2017 vs 2014); Contineum Therapeutics is the larger of the two.
Side-by-Side Comparison
| Metric | Contineum Therapeutics | Novoron Bioscience |
|---|---|---|
| Founded | ||
| Founded | 2017 | 2014 older |
| Headquarters | ||
| Headquarters | San Diego, United States | San Diego, United States |
| Employees | ||
| Employees | 60 larger | 17 |
| Industry | ||
| Industry | Biotechnology | Biopharma, Biotechnology, Health Care |
| Funding Stage | ||
| Funding Stage | Unknown | Seed |
| Total Funding | ||
| Total Funding | Not tracked yet | $17.99M |
| Funding Rounds | ||
| Funding Rounds | 1 | 11 |
| Services | ||
| Services | Therapeutic Research and Development, Clinical Trials Management, Drug Discovery, Patient-Centric Innovation | Development of innovative therapies, Maximized therapeutic benefit exploration, Discovery and development of new drug modalities |
| Target Customers | ||
| Target Customers | Patients with Neurological Disorders, Patients with Inflammatory Diseases, Patients with Fibrotic Conditions, Healthcare Professionals, Collaborative Partners (e.g., Janssen Pharmaceutica NV) | Patients with brain and spinal cord injuries, Individuals experiencing neurodegeneration, Healthcare providers and researchers in neurology |
| Taxonomy | ||
| Taxonomy | Biopharmaceutical, Clinical-stage, Novel Therapies, Oral Small Molecule, Neuroscience Treatments, Inflammation Treatments, Immunology Treatments, Idiopathic Pulmonary Fibrosis, Progressive Multiple Sclerosis, Chronic Pain Treatment, Relapsing-remitting Multiple Sclerosis, Major Depressive Disorder, LPA1 Receptor Antagonist, M1 Receptor Inhibitor, Unmet Medical Needs | Lipoprotein-receptor Drug Development, Neurological Condition Treatment, Central Nervous System Therapeutics, Multiple Sclerosis Research, Spinal Cord Injury Treatment, Alzheimer's Disease Therapy, Neuronal Regeneration, Remyelination Techniques, Orphan Drug Development, Demyelinating Conditions, Tauopathy Solutions, Neuroscience Innovation, CNS Pathologies |
| Website | ||
| Website | contineum-tx.com | novoron.com |
About Contineum Therapeutics
Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical organization committed to developing innovative, oral small molecule therapies targeting neuroscience, inflammation and immunology (NI&I) indications with substantial unmet medical needs. The company's efforts are currently...
About Novoron Bioscience
Novoron Bioscience is carving a niche in the biotechnology sector by pioneering a novel approach to drug development focused on repairing neurological damage. Their innovative work with lipoprotein-receptor drugs targets severe conditions like multiple sclerosis, spinal cord injuries, and Alzheimer'...
We will tell you when either one moves
BounceWatch watches Contineum Therapeutics and Novoron Bioscience for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Contineum Therapeutics and Novoron Bioscience — by email.
Frequently Asked Questions
Compare Contineum Therapeutics with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Contineum Therapeutics on 9 Jun 2026, and Novoron Bioscience on 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.